Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. CytoDyn Inc (CYDY) Message Board

I can't read the entire article as it's behind a p

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 155026
(Total Views: 734)
Posted On: 08/03/2021 4:55:53 PM
Posted By: thriftycents
Re: Borel Fields #98466
I can't read the entire article as it's behind a paywall so take my commentary with that caveat. But the article begins:

Quote:
CytoDyn, a one-time penny stock that has gained both money and notoriety for aggressively pushing an old HIV drug as a treatment for Covid-19, disclosed in a regulatory filing Friday the SEC and DOJ have separately subpoenaed the company and “certain of its executives” as part of investigations into the company’s promotion and marketing practices.



If the article continues in this vein then it is hard to see it as anything other than a rehash of Jeff Manning's article on the Oregonian.

https://www.oregonlive.com/business/2021/07/v...laims.html

They both start with the same premises, "HIV drug pushed for COVID" As we know, we are just a wee bit more than an HIV drug. And "pushed for COVID" Has there been any drug that hasn't been "pushed for COVID"? I mean, we are in the middle of a pandemic. They have thrown the kitchen sink at this virus. I think many of us here would argue that we were pushed for COVID with a superior scientific rationale when compared to many of the other drugs tried! If CCR5 is central to the trafficking of the immune response why wouldn't it make sense to try it in a disease that has universally been categorized as immune chaos? And while we didn't meet our primary endpoints, I would argue that Leronlimab showed more promise than any drug out there when it came to saving lives in the critical patient population. Did they do any due diligence in terms of the patients that have come out as having benefited from taking leronlimab while having COVID?

Perhaps Mr. Manning and Mr. Mast aren't well versed in biotech? Let's check. Mr Manning got his BA in Journalism and has been a reporter at the Oregonian for 27 years. Mr. Mast received his degree from Northwestern University where he covered politics. He then worked for Bloomberg BNA where he covered taxes and politics for a few months. He edited manuscripts for a history professor at Northwestern and then progressed to being an editor at Endpoint News. What qualifies either of these reporters to cover biotech? At best, they are beholden to the subject matter experts they interview and at least in the case of Mr. Manning, he chose not to do so.

Furthermore, there is no lazier form of reporting in my humble opinion than republishing a PR or financial document. Positive or negative this seems like nothing more than a means of using someone else's news to draw views to your site. Again, I don't know if Mr. Mast dug deeper than Mr. Manning as I can't see the full article but did he interview the company? The SEC? The DOJ? Other subject matter experts? Mr. Manning did not. He just cherry picked quotes from the company's 10-K risk section. Sadly, he must have glossed over the many positive items in the 10-K. Was that intentional? Who knows, but it certainly comes across as starting with a negative bias. In fact, in my opinion, it's hard to even fathom someone sifting through our 10K, ignoring all the positive information regarding cancer, NASH, HIV and only honing in on the litigation section without having a goal of shaming the company. Cancer...blah...blah...blah...HIV...blah blah blah...NASH...blah blah blah...Litigation...here we go. Really???

So, I would agree that we do need stronger ammunition to fend off those with nefarious intent. We need validation from a well known trusted 3rd party so these "writers" will have to invalidate those parties in order to defame us. But could you read that 203 page 10-K and walk away with nothing other than the SEC/DOJ lawsuits? Suspect to say the least!




(21)
(0)




CytoDyn Inc (CYDY) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us